Last updated on March 2016

A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type2diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care


Brief description of study

A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type2diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care

Detailed Study Description

Demonstrate whether finerenone QD is superior to placebo QD in delaying the time to first occurrence of cardiovascular mortality and morbidity in subjects with T2DM and the clinical diagnosis of DKD. Randomized at 1:1 ratio. Subjects will take one pill once a day.

Clinical Study Identifier: TX143046

Contact Investigators or Research Sites near you

Start Over

Amanda Davis LPN

Chase Medical Research LLC
Waterbury, CT USA
  Connect »